Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

@article{Yonezawa2015BoostingCI,
  title={Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy},
  author={A. Yonezawa and Suparna Dutt and C. Chester and Jeewon Kim and H. Kohrt},
  journal={Clinical Cancer Research},
  year={2015},
  volume={21},
  pages={3113 - 3120}
}
  • A. Yonezawa, Suparna Dutt, +2 authors H. Kohrt
  • Published 2015
  • Medicine
  • Clinical Cancer Research
    • In the past 5 years, immunomodulatory antibodies have revolutionized cancer immunotherapy. CD137, a member of the tumor necrosis factor receptor superfamily, represents a promising target for enhancing antitumor immune responses. CD137 helps regulate the activation of many immune cells, including CD4+ T cells, CD8+ T cells, dendritic cells, and natural killer cells. Recent studies indicate that the antitumor efficacy of therapeutic tumor-targeting antibodies can be augmented by the addition of… CONTINUE READING
    View on AACR
    clincancerres.aacrjournals.org
    84 Citations
    Highly Influencial Citations
    3
    Background Citations
    40
    Methods Citations
    1
    Results Citations
    1
    84 Citations
    Citation Type

    Citation Type

    Harnessing the innate immune system to treat cancer: enhancement of antibody-dependent cellular cytotoxicity with anti-CD137 Ab.
    • 5
    CD137, an attractive candidate for the immunotherapy of lung cancer
    An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
    • 21
    • PDF
    Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines☆
    • 51
    A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.
    • 31
    • PDF
    Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
    • 39
    Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance
    • 1
    Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
    • 23
    • PDF
    Anti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity
    • 10
    Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression
    • 36
    • PDF

    References

    SHOWING 1-10 OF 99 REFERENCES
    Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137
    • 36
    • PDF
    Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
    • 99
    Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules
    • 71
    • PDF
    Anti-CD137 Monoclonal Antibody Administration Augments the Antitumor Efficacy of Dendritic Cell-Based Vaccines
    • 115
    • PDF
    Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
    • 22
    Combination strategies to enhance antitumor ADCC.
    • 70
    Targeting Spatiotemporal Expression of CD137 on Tumor-infiltrating Cytotoxic T Lymphocytes as a Novel Strategy for Agonistic Antibody Therapy
    • 15
    Eradication of established tumors in mice by a combination antibody-based therapy
    • 167
    CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
    • 198
    Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.
    • 87
    • PDF